New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Dolores IslaMaria D LozanoLuis Paz-AresClara SalasJavier de CastroEsther CondeEnriqueta FelipJavier Gómez-RománPilar GarridoAna Belén EnguitaPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and predictive biomarkers for immunotherapy responses. In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology and the Spanish Society of Medical Oncology have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice.
Keyphrases
- clinical practice
- small cell lung cancer
- advanced non small cell lung cancer
- healthcare
- palliative care
- newly diagnosed
- end stage renal disease
- tyrosine kinase
- ejection fraction
- epidermal growth factor receptor
- loop mediated isothermal amplification
- prognostic factors
- real time pcr
- physical activity
- cell death
- dna damage
- patient reported outcomes
- quality improvement
- gene expression
- single molecule
- copy number
- wild type
- dna methylation
- genome wide
- circulating tumor